8-K: Axsome Therapeutics 2026 Annual Meeting Results

Axsome Therapeutics stockholders approved all proposals at the 2026 Annual Meeting, including director elections and executive compensation.

Summary

• The 2026 Annual Meeting of Stockholders was held on June 5, 2026.
• A quorum was achieved with 43,777,536 shares represented, representing 85.10% of total shares entitled to vote.
• Stockholders elected Mark Saad and Susan Mahony, Ph.D., MBA as Class II directors until 2029.
• Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2026.
• The compensation of named executive officers was approved on a non-binding advisory basis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the filing reports standard administrative outcomes from an annual meeting without material changes to strategy or financial outlook.

Positives

• High voter turnout with 85.10% of shares represented, indicating strong shareholder engagement.
• Strong support for the ratification of the independent auditor with 43,278,147 votes for.
• Successful election of board members and approval of executive compensation packages.

Negatives

• Significant number of withheld votes for director elections (10,286,822 for Mark Saad and 9,070,345 for Susan Mahony).

Risks

• None disclosed in this filing.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing strictly on the results of the annual shareholder meeting.

Industry Context

StockSavvy.ai notes that the successful ratification of auditors and approval of executive compensation are standard procedural outcomes for mid-cap biopharmaceutical companies, reflecting stable corporate governance.

Comparison to Industry Standards

• The 85.10% quorum is consistent with typical participation levels for Nasdaq-listed biotechnology firms.
• The ratification of Deloitte & Touche LLP aligns with industry norms for large-cap and mid-cap life sciences companies.

Corporate Governance

Stakeholder Impact

• Shareholders have confirmed the current board and executive compensation structure.
• The company maintains its existing relationship with its independent auditor.

Next Steps

• Directors will serve until the 2029 annual meeting.
• Deloitte & Touche LLP will continue as the independent auditor for the fiscal year ending December 31, 2026.

Key Dates

Keywords

Axsome Therapeutics, Annual Meeting, Proxy Results, Corporate Governance, AXSM